Your browser doesn't support javascript.
loading
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen, Xi; Kong, Haiying; Luo, Linxiang; Han, Shuiyun; Lei, Tao; Yu, Haifeng; Guo, Na; Li, Cong; Peng, Shuailing; Dong, Xiaowu; Yang, Haiyan; Wu, Meijuan.
Affiliation
  • Chen X; Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
  • Kong H; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Luo L; Department of Pharmacy, Zhejiang Medical and Health Group Hangzhou Hospital (Hangzhou Hanggang Hospital), Hangzhou, China.
  • Han S; Department of Hematology, Zhejiang Quhua Hospital, Quhua, China.
  • Lei T; Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
  • Yu H; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Guo N; Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
  • Li C; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Peng S; Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
  • Dong X; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Yang H; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Wu M; Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No. 1 Banshan East Road, Hangzhou, China.
BMC Cancer ; 22(1): 9, 2022 Jan 03.
Article de En | MEDLINE | ID: mdl-34980000
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladie de Hodgkin / Antigène CD274 / Ligand-2 de la protéine-1 de mort cellulaire programmée / Inhibiteurs de points de contrôle immunitaires Type d'étude: Observational_studies / Risk_factors_studies Limites: Adult / Female / Humans / Male / Middle aged Langue: En Journal: BMC Cancer Sujet du journal: NEOPLASIAS Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladie de Hodgkin / Antigène CD274 / Ligand-2 de la protéine-1 de mort cellulaire programmée / Inhibiteurs de points de contrôle immunitaires Type d'étude: Observational_studies / Risk_factors_studies Limites: Adult / Female / Humans / Male / Middle aged Langue: En Journal: BMC Cancer Sujet du journal: NEOPLASIAS Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni